Ibrutinib
Back to searchMolecule Structure
Scientific Name
Ibrutinib
Description of the Drug
Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s Macroglobulinemia.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09053
http://www.drugbank.ca/drugs/DB09053
Brand Name(s)
Imbruvica
Company Owner(s)
Zydus Worldwide Dmcc, Pharmacyclics Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Tyrosine-protein kinase BTK | SINGLE PROTEIN | INHIBITOR | CHEMBL5251 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL201859 | |
PharmGKB | PA166121346 | |
DrugBank | DB09053 | |
PubChem: Thomson Pharma | 49837088 | |
PubChem | 24821094 | |
LINCS | LSM-45830 | |
Nikkaji | J2.980.554G | |
PDBe | 1E8 | |
BindingDB | 50357312 | |
EPA CompTox Dashboard | DTXSID60893450 | |
DrugCentral | 4810 | |
Brenda | 213563 | |
ChemicalBook | CB12515873 | |
Guide to Pharmacology | 6912 | |
rxnorm | IMBRUVICA | IBRUTINIB |
ChEBI | 76612 | |
ZINC | ZINC000035328014 |